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Background: The utility of biomarkers in prediction of cardiac events in asymptomatic adults is unclear. We examined if the predictive value of 
biomarkers may depend on the atherosclerotic burden.
Methods: We studied 1302 asymptomatic persons (mean age 59 years, 47% female) with coronary calcium (CAC) scans, measures of biomarkers 
including BNP, IL-6, hs-CRP, myeloperoxidase, and plasminogen activator-1, and follow-up for coronary heart disease (CHD) and cardiovascular 
disease (CVD) events over 4.0±0.7 years. Cardiac event risk was determined for those above versus below the median biomarker score (1 point for 
each biomarker in the highest quartile), stratified by CAC score (<10, 10-99, and 100+). Cox regression examined the combined association of the 
biomarker index and CAC on risk of events.
Results: Overall, persons at or above (2-5) (high) vs. below the median (0-1) (low) biomarker index had greater rates of CHD (4.5% vs. 2.0%, 
p=0.01) and CVD (4.9% vs. 2.6%, p=0.03) with unadjusted HRs (95% CI) of 2.4(1.2-4.5) and 2.0 (1.1-3.5), respectively, however these were 
attenuated after risk factor adjustment. The biomarker index stratified risk in those with CAC scores of 10-99; in those with higher levels of CAC 
(>100), event risk was elevated regardless of biomarker level (table). 
Hazard Ratios (HRs) for CHD and CVD Events by CAC / Biomarker Category
CAC / Biomarker Category CHD events, % (n) HR (95% CI) CVD events, % (n) HR (95% CI)
CAC 0-9 (all) 0.4 (3) 1.0 (Reference) 0.6 (4) 1.0 (Reference)
CAC 10-99, low biomarkers 0.6 (1) 1.2 (0.1-11.4) 2.3 (4) 3.3 (0.8-13.2)
CAC 10-99, high biomarkers 5.8 (6) 10.1 (2.5-41)** 5.8 (6) 7.2 (2.0-26)**
CAC >100, low biomarkers 8.1 (13) 16.6 (4.5-62)** 8.8 (14) 12.3 (3.9-40)**
CAC >100, high biomarkers 11.5** (15) 18.8 (5.0-70)** 13.0** (17) 14.9 (4.7-48)**
*p<0.05, ** p<0.01 comparing event rates across CAC/biomarker categories, or for HR’s relative to reference category.
Conclusion: Biomarkers may stratify risk of cardiac events best in persons with mild atherosclerosis.
